New Triple-Drug approach targets leukemia in vulnerable patients
Disease control
Terminated
This early-phase study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The study was stopped early, so resul…
Phase: PHASE1 • Sponsor: Brian Jonas • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC